Terms: = Leukemia AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Treatment
976 results:
1. On the mechanism of wogonin against acute monocytic leukemia using network pharmacology and experimental validation.
Wang X; Wang Y; Chen J; Wang Q; Liu Z; Yin Y; Yang T; Shen T; Sa Y
Sci Rep; 2024 May; 14(1):10114. PubMed ID: 38698063
[TBL] [Abstract] [Full Text] [Related]
2. Regulation of Hypoxia Dependent Reprogramming of Cancer Metabolism: Role of HIF-1 and Its Potential Therapeutic Implications in leukemia.
Pandey S; Singh R; Habib N; Tripathi RM; Kushwaha R; Mahdi AA
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1121-1134. PubMed ID: 38679971
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive characterization of immunogenic cell death in acute myeloid leukemia revealing the association with prognosis and tumor immune microenvironment.
Chen Y; Qiu X; Liu R
BMC Med Genomics; 2024 Apr; 17(1):107. PubMed ID: 38671491
[TBL] [Abstract] [Full Text] [Related]
4. [Research Progress of Targeted Therapy for Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma --Review].
Chen D; Wang MY; Tian C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
[TBL] [Abstract] [Full Text] [Related]
5. [Effect of Shikonin on Autophagy and Apoptosis of Human Promyelocytic leukemia Cells].
Chen Y; Xie XM; Zhang XL; Zhang XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):416-421. PubMed ID: 38660845
[TBL] [Abstract] [Full Text] [Related]
6. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic leukemia.
Lu Z; Lai Q; Li ZF; Zhong MY; Jiang YL; Feng LY; Zha J; Yao JW; Li Y; Deng XM; Xu B
Curr Med Sci; 2024 Apr; 44(2):298-308. PubMed ID: 38619682
[TBL] [Abstract] [Full Text] [Related]
7. A prognostic model of idiopathic pulmonary fibrosis constructed based on macrophage and mitochondria-related genes.
Bao Y; Yang S; Zhao H; Wang Y; Li K; Liu X; Zhang W; Zhu X
BMC Pulm Med; 2024 Apr; 24(1):176. PubMed ID: 38609879
[TBL] [Abstract] [Full Text] [Related]
8. Discovery of Potent and Selective pi3kδ Inhibitors for the treatment of Acute Myeloid leukemia.
Tang Y; Zheng Y; Hu X; Zhao H; Cui S
J Med Chem; 2024 Apr; 67(8):6638-6657. PubMed ID: 38577724
[TBL] [Abstract] [Full Text] [Related]
9. Gene expression profiling on CML patients with Philadelphia translocation.
Alkhatabi H; Aldahlawi S; Hazzazi MS; Alsolami R; Elaimi A; Almashjary MN; Alserihi R; Alkhatabi HA; Alquthami ME; Daous YM; Bahashwan S; Yasin EB; Barefah A; Alsayes F
Eur Rev Med Pharmacol Sci; 2024 Feb; 28(4):1340-1355. PubMed ID: 38436167
[TBL] [Abstract] [Full Text] [Related]
10. Duvelisib: A comprehensive profile.
Aljohar HI; Al-Abdullah E; Alzoman NZ; Darwish HW; Darwish IA
Profiles Drug Subst Excip Relat Methodol; 2024; 49():19-40. PubMed ID: 38423708
[TBL] [Abstract] [Full Text] [Related]
11. [MiR-217 Targeting pi3k/Akt Pathway Enhances Sensitivity of Adriamycin to Acute Myeloid leukemia].
Gan DY; Wu J; Zhou M; Chen W; Jiang W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):39-44. PubMed ID: 38387897
[TBL] [Abstract] [Full Text] [Related]
12. A molecular circuit linking the BCR to the NAD biosynthetic enzyme NAMPT is an actionable target in Richter syndrome.
Messana VG; Fascì A; Vitale N; Micillo M; Rovere M; Pesce NA; Martines C; Efremov DG; Vaisitti T; Deaglio S
Blood Adv; 2024 Apr; 8(8):1920-1933. PubMed ID: 38359376
[TBL] [Abstract] [Full Text] [Related]
13. Licochalcone A induces mitochondria-dependent apoptosis and interacts with venetoclax in acute myeloid leukemia.
Li Y; Zhao M; Lin Y; Jiang X; Jin L; Ye P; Lu Y; Pei R; Jiang L
Eur J Pharmacol; 2024 Apr; 968():176418. PubMed ID: 38350590
[TBL] [Abstract] [Full Text] [Related]
14. treatment of Double-Refractory Chronic Lymphocytic leukemia-An Unmet Clinical Need.
Zygmunciak P; Robak T; Puła B
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338868
[TBL] [Abstract] [Full Text] [Related]
15. Bioactive triterpenoid compounds of Poria cocos (Schw.) Wolf in the treatment of diabetic ulcers via regulating the pi3k-AKT signaling pathway.
Ding X; Li S; Huang H; Shen J; Ding Y; Chen T; Ma L; Liu J; Lai Y; Chen B; Wang Y; Tan Q
J Ethnopharmacol; 2024 May; 325():117812. PubMed ID: 38301984
[TBL] [Abstract] [Full Text] [Related]
16. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Yacoub A; Borate U; Rampal RK; Ali H; Wang ES; Gerds AT; Hobbs G; Kremyanskaya M; Winton E; O'Connell C; Goel S; Oh ST; Schiller G; McCloskey J; Palmer J; Holmes H; Hager S; Assad A; Erickson-Viitanen S; Zhou F; Daver N
Blood Adv; 2024 Mar; 8(6):1515-1528. PubMed ID: 38290135
[TBL] [Abstract] [Full Text] [Related]
17. Long non-coding RNA small nucleolar RNA host gene 29 drives chronic myeloid leukemia progression via microRNA-483-3p/Casitas B-lineage Lymphoma axis-mediated activation of the phosphoinositide 3-kinase/Akt pathway.
Feng X; Yang L; Liu X; Liu M; Liu L; Liu J; Luo J
Med Oncol; 2024 Jan; 41(2):60. PubMed ID: 38252204
[TBL] [Abstract] [Full Text] [Related]
18. C-X-C motif chemokine receptor 4 inhibition promotes the effect of plantamajoside in hepatocellular carcinoma.
Sun J; Liu W; Fu H; Li Y; Huang J; Wang Y; Zhu L
Arab J Gastroenterol; 2024 Feb; 25(1):28-36. PubMed ID: 38220479
[TBL] [Abstract] [Full Text] [Related]
19. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis.
Ren W; Wan H; Own SA; Berglund M; Wang X; Yang M; Li X; Liu D; Ye X; Sonnevi K; Enblad G; Amini RM; Sander B; Wu K; Zhang H; Wahlin BE; Smedby KE; Pan-Hammarström Q
Leukemia; 2024 Mar; 38(3):610-620. PubMed ID: 38158444
[TBL] [Abstract] [Full Text] [Related]
20. Inhibition of pi3k-AKT-mTOR pathway and modulation of histone deacetylase enzymes reduce the growth of acute myeloid leukemia cells.
Şansaçar M; Sağır H; Gencer Akçok EB
Med Oncol; 2023 Dec; 41(1):31. PubMed ID: 38148433
[TBL] [Abstract] [Full Text] [Related]
[Next]
